The National Pharmaceutical Pricing Authority (NPPA), operating under the Department of Pharmaceuticals, on Friday, 13 November 2026, directed strict monitoring of the implementation of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs, whose reduced prices came into effect on 9 November. The move aims to ensure that the benefit of lower drug prices reaches cancer patients across India, following a 30 per cent cap on trade margins introduced through an NPPA order dated 17 October.

What the Order Mandates

All manufacturers, retailers, dealers, stockists, hospitals, and medical institutions have been directed to comply with the revised prices and to prominently display the updated price lists at their premises and on their websites. The latest revised price lists, based on submissions received from companies up to 11 November, are publicly accessible on the NPPA website and the Pharma Sahi Daam app and portal.

State Drug Controllers (SDCs) have been specifically directed to monitor compliance by manufacturers, dealers, hospitals, and medical institutions. According to an official statement, 'Any violation may attract overcharging proceedings under the provisions of Drugs (Prices Control) Order, 2013.' SDCs have also been asked to submit their Action Taken Reports to NPPA by 16 November.

Scale of Price Reductions

By 9 November, 85 pharmaceutical companies had reported revised maximum retail prices (MRPs) for 121 of the 137 medicines, covering 1,366 stock-keeping units (SKUs). The highest reported price reduction stands at 96.45 per cent, and more than 650 formulations recorded MRP reductions exceeding 50 per cent. The largest cluster of reductions fell in the 50–75 per cent range.

The 30 per cent trade margin cap applies across the entire pharmaceutical supply chain — including retail and hospital pharmacies — and covers all listed medicines regardless of dosage form, such as tablets or injections, and whether sold individually or in combinations.

Estimated Patient Savings

According to official estimates, the savings for patients are projected at ₹3,541 crore. These figures have been calculated by comparing original and revised prices and applying the difference to sales volumes recorded between April 2025 and March 2026. The magnitude of these savings underscores how dramatically trade margins had inflated retail prices for critical oncology medicines beyond their base cost.

How to Report Violations

The NPPA has set up multiple channels for patients and stakeholders to flag non-compliance. Complaints regarding overcharging, shortage, or non-availability of medicines can be reported through the Pharma Sahi Daam app/portal, the NPPA helpline at 1800-111-255 (toll-free), or via email at monitoring-nppa[at]gov[dot]in. The authority has underlined that all grievances will be acted upon.

Background and Significance

The TMR mechanism is distinct from price controls under the Drug Price Control Order, which caps prices of scheduled essential medicines. Non-scheduled drugs — which include many anti-cancer therapies — were previously outside such direct oversight, allowing trade margins to balloon along the supply chain. This is the latest expansion of the TMR framework, which the NPPA has used to bring down prices of medical devices and other drug categories in prior years. Notably, this intervention specifically targets oncology drugs, where out-of-pocket expenditure has been a leading cause of catastrophic health spending for Indian households.

With SDC reports due by 16 November, the NPPA's enforcement response in the coming days will be a key indicator of whether these price cuts translate into real-world relief at hospital counters and retail pharmacies.